Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (701-710 of 962) with videos related to

Pageof 97
Sort By:
JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.
Circulation|June 30, 2022
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of AlirocumabEmil Hagström, P Gabriel Steg, Michael Szarek, et al.
Circulation|October 29, 2008
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trialsShamir R Mehta, William E Boden, John W Eikelboom, et al.
The Lancet. Neurology|September 17, 2022
Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort studyCristina Hobeanu, Philippa C Lavallée, Hugo Charles, et al.
Neurology|October 13, 2020
Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian PopulationsTakao Hoshino, Shinichiro Uchiyama, Lawrence K S Wong, et al.
European Heart Journal. Acute Cardiovascular Care|October 21, 2020
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategyBatric Popovic, Emmanuel Sorbets, Jeremie Abtan, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
Circulation|September 1, 2016
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)Marc P Bonaca, Shinya Goto, Deepak L Bhatt, et al.
JACC. Cardiovascular Interventions|August 2, 2016
Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With StentsJennifer Yu, Usman Baber, Ioannis Mastoris, et al.
American Journal of Preventive Cardiology|June 15, 2026
Small, dense LDL-C as a predictor of cardiovascular risk and benefit of alirocumab in patients with recent acute coronary syndrome receiving optimized statin treatmentGregory G Schwartz, Michael Szarek, Christa M Cobbaert, et al.
Pageof 97

Showing results (701-710 of 962) with videos related to

Sort By:
Pageof 97
JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.
Circulation|June 30, 2022
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of AlirocumabEmil Hagström, P Gabriel Steg, Michael Szarek, et al.
Circulation|October 29, 2008
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trialsShamir R Mehta, William E Boden, John W Eikelboom, et al.
The Lancet. Neurology|September 17, 2022
Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort studyCristina Hobeanu, Philippa C Lavallée, Hugo Charles, et al.
Neurology|October 13, 2020
Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian PopulationsTakao Hoshino, Shinichiro Uchiyama, Lawrence K S Wong, et al.
European Heart Journal. Acute Cardiovascular Care|October 21, 2020
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategyBatric Popovic, Emmanuel Sorbets, Jeremie Abtan, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
Circulation|September 1, 2016
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)Marc P Bonaca, Shinya Goto, Deepak L Bhatt, et al.
JACC. Cardiovascular Interventions|August 2, 2016
Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With StentsJennifer Yu, Usman Baber, Ioannis Mastoris, et al.
American Journal of Preventive Cardiology|June 15, 2026
Small, dense LDL-C as a predictor of cardiovascular risk and benefit of alirocumab in patients with recent acute coronary syndrome receiving optimized statin treatmentGregory G Schwartz, Michael Szarek, Christa M Cobbaert, et al.
Pageof 97